

1 **mRNA vaccines effectiveness against COVID-19 hospitalizations and deaths in older**
2 **adults: a cohort study based on data-linkage of national health registries in Portugal**

3 **Authors:** Baltazar Nunes¹, Ana Paula Rodrigues¹, Irina Kislaya¹, Camila Cruz², André
4 Peralta-Santos³, João Lima², Pedro Pinto Leite³, Duarte Sequeira², Carlos Matias Dias¹,
5 Ausenda Machado¹

6 1 Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo
7 Jorge, Lisbon, Portugal

8 2 Serviços Partilhados do Ministério da Saúde, Lisbon, Portugal

9 3 Direção de Serviços de Informação e Análise, Direção-Geral da Saúde, Lisbon,
10 Portugal

11

12 **Abstract**

13 Background: We used electronic health registries to estimate the mRNA vaccine
14 effectiveness (VE) against COVID-19 hospitalizations and deaths in older adults.

15 Methods: We established a cohort of individuals aged 65 and more years, resident in
16 Portugal mainland through data linkage of eight national health registries. For each
17 outcome, VE was computed as one minus the confounder-adjusted hazard ratio,
18 estimated by time-dependent Cox regression.

19 Results: VE against COVID-19 hospitalization ≥ 14 days after the second dose was 94%
20 (95%CI 88 to 97) for age-group 65-79 years old (yo) and 82% (95%CI 72 to 89) for ≥ 80
21 yo. VE against COVID-19 related deaths ≥ 14 days after second dose was 96% (95%CI
22 92 to 98) for age-group 65-79 yo and 81% (95%CI 74 to 87), for ≥ 80 yo individuals. No
23 evidence of VE waning was observed after 98 days of second dose uptake.

24 Conclusions: mRNA vaccine effectiveness was high for the prevention of
25 hospitalizations and deaths in age-group 65-79 yo and ≥ 80 yo with a complete
26 vaccination scheme, even after 98 days of second dose uptake.

27 **Introduction**

28 Vaccination is essential to reduce COVID-19 burden and its complications. The first
29 published observational studies showed that the mRNA (Pfizer-BioNTech and
30 Moderna) vaccines were highly effective in preventing SARS-CoV-2 infections and
31 severe outcomes in older adults, even with partial vaccination [1,2]. Vaccine
32 effectiveness (VE) against hospital admissions and COVID-19 related mortality in
33 elderly populations varied between 43-64% for the partial vaccination and 94-97% for
34 the completed vaccination scheme in December 2020-April 2021 [1,3-5].

35 Recent research showed a decrease in VE against the Delta SARS-CoV-2 variant of
36 concern (VOC) and some evidence of waning immunity for symptomatic infections in
37 the general population [6,7], but sustained VE estimates against hospitalizations [7,8].
38 However, most studies of VE against severe forms of COVID-19 had a limited follow-up
39 period after complete vaccination [1,4,5], estimated VE of a single dose [2,3] or
40 focused on the general population [7,8] and few considered COVID-19 related
41 mortality outcome and high-risk groups. Understanding VE against outcomes of
42 various severity levels in diverse epidemiological contexts for high-risk groups is
43 important to inform public health measures.

44 This study aimed to estimate mRNA (Pfizer-BioNTech and Moderna) COVID-19 vaccines
45 effectiveness against hospitalizations and COVID-19 related deaths in Portuguese
46 adults aged 65 years old or more in February-August 2021.

47

48 **Methods**

49 *Study settings*

50 We developed a cohort study, based on linkage of electronic health registries. The
51 target population included individuals aged 65 or more years old (yo) resident in
52 private households in Portugal mainland eligible for vaccination.

53 We excluded from the analysis individuals with improbable ages (more than 110 yo),
54 institutionalized, residents in autonomous regions of Madeira and Azores and with
55 previous SARS-CoV-2 infection. Additionally, to improve completeness and quality of
56 the health records, we included only the subset of National Health Service frequent
57 users[9] for 65-79 yo. For the ≥ 80 yo cohort, data analysis was restricted to those with
58 at least one vaccine uptake in the last five years for influenza or pneumococcal
59 vaccines.

60 The study period was defined based on the vaccination campaign roll-out calendar,
61 starting on the 2nd of February 2021 for ≥ 80 yo cohort and on the 30th of March 2021
62 for the 65-79 yo cohort, up to the date of the last observed event for each outcome
63 (Table S1).

64

65 *Data sources*

66 Eight national electronic health registries were used in this study, including the
67 National Health Service User (NHSU) databaset, the vaccination registry (VACINAS), the
68 National Information System for Epidemiologic Surveillance (BI-SINAVE), the National
69 Death Registry (SICO), the Primary Care Information System (SIM@SNS), the Primary
70 Care Clinical Monitoring System of COVID-19 Patients in Home Isolation (BI-TRACE
71 COVID-19), the National Database of Medicine and Treatment Prescriptions (PEM) and

72 the national database of hospital discharges (BIMIH). All the data from these registries
73 was centralized in one analytic system (CovidAnalytics).

74

75 Data extraction and linkage was performed on 13th August 2021 by the Shared Services
76 of the Ministry of Health in accordance with legal and ethical requirements. All data
77 were anonymized prior to statistical analysis by the research team. The study protocol
78 was approved by the Data Protection Officer and the Ethical Committee of the
79 Instituto Nacional de Saúde Doutor Ricardo Jorge (INSA).

80 *Variables*

81 *Outcome*

82 A COVID-19 hospitalization was defined as admission for at least 24h with COVID-19 as
83 the primary diagnosis (ICD10 code U07.1) [10], and a previous positive reverse
84 transcription polymerase chain reaction (RT-PCR) test. All-cause death with positive
85 RT-PCR test occurred within previous 30 days were considered COVID-related death
86 [4].

87 *Exposure*

88 Exposure to mRNA vaccine was categorized into three levels: unvaccinated (no dose
89 registered), partially vaccinated (14 days after the first dose or less than 14 days after
90 the 2nd dose) and with complete vaccination (14 days after the 2nd dose uptake). To
91 evaluate the hypothesis of vaccine effectiveness waning, time starting at 14 days after
92 the second dose was stratified in 28-day intervals.

93 *Confounding*

94 Age groups, sex, municipality level European Deprivation Index (EDI) quintile [11],
95 health region, number of chronic conditions (among anemia, asthma, cancer, cardiac

96 disease, stroke, dementia, diabetes, hypertension, chronic liver disease,
97 neuromuscular disease, renal disease, rheumatologic disease pulmonary disease,
98 obesity, immunodeficiency, tuberculosis), number of laboratory SARS-CoV-2 tests
99 during 2021, previous influenza or pneumococcal vaccine uptake in the last 3 years
100 were considered as potential confounders.

101 *Statistical methods*

102 We compared individual characteristics at baseline by vaccine exposure status and
103 estimated the COVID-19 hospitalization and death rates per 1000 person-years for
104 unvaccinated exposure and mRNA vaccine exposure period according to the number of
105 doses. Individuals vaccinated with other vaccine brands contributed to unvaccinated
106 exposure prior to vaccination. Given the different observational periods, we estimated
107 VE separately for two age-group cohorts: 65-79 and ≥ 80 yo. VE was computed as one
108 minus the confounder-adjusted hazard ratio, for each outcome, estimated by time-
109 dependent Cox regression [2] with time dependent vaccine exposure, adjusted for
110 confounding using 7-day periods as strata. Statistical analysis was performed in R
111 Computing Environment, version 4.0.5.

112 **Results**

113 *Participants*

114 We enrolled 1,409,831 persons aged 65-79 yo and 470,520 aged ≥ 80 yo in the study
115 (Figure S1, S2). Among 65-79 yo, 641,119 (45.5%) received the Pfizer-BioNTec, 112,132
116 (8.0%) the Moderna and 531,342 (37.7%) other vaccines, while 125,338 (8.9%)
117 remained unvaccinated. In the ≥ 80 yo cohort 5.7% were unvaccinated whereas 80.4%,
118 11.8% and 2.1% received at least one dose of Pfizer-BioNTec, Moderna or other

119 vaccines, respectively. We present the roll-out of vaccine coverage in supplementary
120 files (Figure S3).

121 The most relevant differences between unvaccinated and vaccinated individuals were
122 observed in their distribution by health region, the number of chronic conditions and
123 previous vaccination for influenza or pneumococcal in the last 3 years (Table 1 & 2).

124 The exposure time to the second dose varied between the two age cohorts, with a
125 median of 78 days (IQR 71 to 94) for the 65-79 yo and 125 days (IQR 112 to 145) for
126 the ≥ 80 yo cohort (Table S2).

127 During the observation period, a total of 218 COVID-19 hospital admissions and 121
128 deaths were registered for the 65-79 yo cohort whereas among the ≥ 80 yo 836 cases
129 were hospitalized with primary COVID-19 diagnosis and 701 died (Figure S4, S5).

130

131 *Vaccine effectiveness against hospitalizations with primary diagnosis of COVID-19*

132 For the 65-79 yo, adjusted mRNA VE against COVID-19 hospitalization was 78% (95% CI
133 61 to 87) for partial vaccination and 94% (95% CI 88 to 97) for complete vaccination
134 scheme (Table3). For ≥ 80 yo cohort, we observed lower VE estimates for
135 hospitalization, 55% (95% CI 36 to 69) for partial and 82% (95% CI 72 to 89) for
136 complete vaccination, respectively (Table 4).

137 For both age groups, we observed a statistically significant increase of protection
138 between partial and complete vaccination. Additionally, for the ≥ 80 yo cohort, we did
139 not observe any statistical significant difference between VE estimates in persons with
140 98 or more days after the second dose (VE: 88%) compared with those with 14 to 41
141 days after the second dose (VE: 81%) (Table 4).

142 *Vaccine effectiveness against COVID-19 related deaths*

143 Adjusted VE against COVID-19 related deaths, for the cohort of 65-79 yo, increased
144 from 77% (95% CI 56 to 88) to 96% (95% CI 92 to 98) from partial to complete mRNA
145 vaccination.

146 For the ≥ 80 yo VE against COVID-19 related deaths was 56% (95% CI 35 to 70) and 81%
147 (95% CI 74 to 87), for partial and complete vaccinations, respectively. The risk of
148 COVID-19 related deaths decreased significantly from partial to complete vaccination
149 schemes in both age groups.

150 VE against COVID-19 related deaths, among those with 98 days or more after the
151 second dose (VE=73%), was slightly lower than for those with 14 to 41 days (VE=86%)
152 after the second dose, but the difference was not statistically significant (Table 4).

153 **Discussion**

154 We present VE estimates of Pfizer-BioNTech or Moderna vaccines against severe
155 COVID-19 outcomes for the Portuguese population aged 65 and older from February to
156 August 2021. Our results indicate moderate to high protection against hospitalization
157 with a primary diagnosis of COVID-19 (VE: 55-78%) and COVID-19 related deaths (VE:
158 56-77%) for partial mRNA vaccination and high levels of protection for the complete
159 vaccination scheme (82-94% for hospitalization and 81-96% for mortality,
160 respectively), supporting the advantage of complete vaccination.

161 For the complete vaccination scheme, our results for 65-79 yo are comparable to other
162 studies conducted in Israel and the USA in population aged 65 and older, that reported
163 Pfizer-BioNTech VE against hospitalizations of 97.9% and 94%, respectively [1,5].

164

165 The slight VE differences between our study and others may be explained by random
166 variation, different study designs, observational periods and different epidemiological
167 and virological contexts. Our study comprises a period of high COVID-19 incidence
168 observed at the beginning of the vaccination campaign, corresponding to the third
169 COVID-19 peak in January-February 2021 and a predominant Alpha VOC circulation,
170 but also includes the period of its replacement by the SARS-CoV-2 Delta variant which
171 in Portugal started in May 2021 [12].

172 mRNA VE estimates varied by age group for both severe outcomes targeted by this
173 study, being about 23 percentage points (pp) lower for hospitalizations and 21 pp
174 lower for COVID-19 related deaths for partial vaccination in the older cohort. For the
175 complete vaccination, differences detected between age cohorts were smaller in
176 magnitude, with 12 pp for hospitalizations and 15 pp for mortality.

177 Lower VE estimates observed in the older age cohort may be related to age-associated
178 immunosenescence or waning of vaccine-induced protection, since ≥ 80 yo cohort in
179 Portugal was targeted by the vaccination campaign earlier and had more prolonged
180 exposure to the second dose. We measured VE by time since the second dose for the
181 cohort ≥ 80 yo. Results suggest sustained VE levels up to 98 days (3 months) after the
182 second dose for hospitalizations and a non-significant decrease for COVID-19 related
183 deaths.

184 These results are consistent with recently published results on VE against
185 hospitalization in the US general population [8]. Nevertheless, we cannot rule out bias
186 in the VE estimates for the 98 days plus vaccine exposure class due to delayed data
187 updates in hospitalizations and deaths.

188

189 The study has several limitations, some of which are related with the electronic
190 registries used and their data quality. The main dataset used to link data was the
191 NHSU, that contains the unique mandatory health number attributed to each
192 individual in Portugal. However, as referred, the NHSU database could have update
193 issues, and occasional register of NHS users, that could artificially increase the number
194 of individuals in a given cohort. Several exclusion criteria were applied to overcome
195 this limitation and the final cohort was comparable to the National Statistics Office
196 estimates for individuals aged 65 and more years (Table S3) [13].

197 The delay of information on hospital discharge might contribute to underrepresenting
198 this specific outcome and underestimating incidence rates for the more recent
199 observation period. Although we did not find any reason for different delay in
200 discharge information registry between vaccinated and unvaccinated, there is a
201 possibility of a differential bias if vaccinated had a lower hospitalization time when
202 compared to non-vaccinated. Our data do not allow us to estimate the length of
203 hospitalization for each group and mitigate this potential bias.

204 Although we adjusted VE for calendar time, chronic conditions, and other relevant
205 confounders, some residual confounding bias could be present mainly regarding the
206 absence of information on personal protective measures like mask use, hand washing,
207 and social distancing.

208 Finally, we were not able to estimate VE for other vaccine brands in 65-79 yo cohort
209 due to their recent introduction and short follow up period, mainly after complete
210 vaccination scheme.

211

212

213 In conclusion, our study supports high mRNA vaccine effectiveness for the prevention
214 of COVID-19 hospitalizations and deaths in population with 65 or more years of age
215 with a complete vaccination. Up 98 days (3 months) of second dose uptake, we did not
216 found evidence of VE reduction. Use of cohort study designs based on nationwide
217 health records linkage is a feasible and timely approach to monitor VE.

218

219 **Reference**

220 [1] Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and
221 effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and
222 COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination
223 campaign in Israel: an observational study using national surveillance data.
224 Lancet 2021;397:1819–29. doi:10.1016/S0140-6736(21)00947-8.

225 [2] Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, et al. Interim findings
226 from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital
227 admissions in Scotland: a national prospective cohort study. Lancet
228 2021;397:1646–57. doi:10.1016/S0140-6736(21)00677-2.

229 [3] Bernal JL, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al.
230 Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-
231 19 related symptoms, hospital admissions, and mortality in older adults in
232 England: test negative case-control study. BMJ 2021;373.
233 doi:10.1136/BMJ.N1088.

234 [4] Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, et al.

235 Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against
236 symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario,
237 Canada: test negative design study. *BMJ* 2021;374:n1943.
238 doi:10.1136/BMJ.N1943.

239 [5] Tenforde MW, Olson SM, Self WH, Talbot HK, Lindsell CJ, Steingrub JS, et al.
240 Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19
241 Among Hospitalized Adults Aged ≥ 65 Years — United States, January–March
242 2021. *MMWR Morb Mortal Wkly Rep* 2021;70:674–9.
243 doi:10.15585/MMWR.MM7018E1.

244 [6] Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al.
245 Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *N Engl J*
246 *Med* 2021. doi:10.1056/nejmoa2108891.

247 [7] Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in
248 Scotland: demographics, risk of hospital admission, and vaccine effectiveness.
249 *Lancet* 2021;397:2461–2. doi:10.1016/s0140-6736(21)01358-1.

250 [8] Tenforde MW, Self WH, Naioti EA, Ginde AA, Douin DJ, Olson SM, et al.
251 Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against
252 COVID-19 Associated Hospitalizations Among Adults — United States, March–
253 July 2021. *MMWR Morb Mortal Wkly Rep* 2021;70.
254 doi:10.15585/mmwr.mm7034e2.

255 [9] Administração Central do Sistema de Saúde [ACSS]. SDM - BI de Conceitos 2021.
256 https://sdm.min-saude.pt/bi.aspx?id_con=90 (accessed August 27, 2021).

- 257 [10] Administração Central do Sistema de Saude. Codificação clinica de doentes
258 internados com diagnóstico de COVID-19. Circular normativa 2021.
- 259 [11] Ribeiro A, Launay L, Guillaume G, Launoy G, Barros H. The Portuguese version of
260 the European Deprivation Index: Development and association with all-cause
261 mortality. PLoS One 2018;13. doi:10.1371/JOURNAL.PONE.0208320.
- 262 [12] National Institute of Health (INSA) Dr. Ricardo Jorge. Genetic diversity of the
263 novel coronavirus SARS-CoV-2 (COVID-19) in Portugal. Lisbon: 2021.
- 264 [13] População residente (N.º) por Local de residência (NUTS - 2013), Sexo e Grupo
265 etário; Anual - INE, Estimativas anuais da população residente 2019. n.d.
- 266

267 Tables

268 Table 1: Distribution of 65 to 79 years of age cohort individuals by age group, sex, health
 269 region, municipality level European Deprivation index, number of chronic diseases*, number of
 270 SARS-CoV-2 tests performed in 2021, influenza or pneumococcal vaccine uptake in the last
 271 three years.

	mRNA vaccines	Unvaccinated
	No. 753,151	No. 125,338
Age (years), median (IQR)	71.0 (68.0 - 75.0)	71.0 (68.0 - 75.0)
Age group, (%)		
65-69	294,438 (39.1%)	47,515 (37.9%)
70-74	255,355 (33.9%)	42,898 (34.2%)
75-79	203,358 (27.0%)	34,925 (27.9%)
Sex Male, n (%)	329,379 (43.7%)	55,749 (44.5%)
Region, n (%)		
Norte	320,327 (42.5%)	28,675 (22.9%)
Centro	132,741 (17.6%)	20,831 (16.6%)
Lisbon & Tagus Valley	231,906 (30.8%)	45,853 (36.6%)
Alentejo	34,876 (4.6%)	5,150 (4.1%)
Algarve	29,081 (3.9%)	13,321 (10.6%)
Missing	4,220 (0.6%)	11,508 (9.2%)
EDI Quintile, n (%)		
Q1 (least deprived)	117,775 (15.6%)	15,159 (12.1%)
Q2	111,710 (14.8%)	15,187 (12.1%)
Q3	110,228 (14.6%)	14,778 (11.8%)

	mRNA vaccines	Unvaccinated
	No. 753,151	No. 125,338
Q4	219,931 (29.2%)	30,949 (24.7%)
Q5 (most deprived)	189,287 (25.1%)	37,757 (30.1%)
Missing	4,220 (0.6%)	11,508 (9.2%)
Number of chronic diseases, n (%)		
0	172,920 (23.0%)	59,424 (47.4%)
1	199,357 (26.5%)	27,649 (22.1%)
2	185,810 (24.7%)	19,616 (15.7%)
3	118,451 (15.7%)	11,153 (8.9%)
4	52,233 (6.9%)	5,008 (4.0%)
5+	24,380 (3.2%)	2,488 (2.0%)
Number of SARS-CoV-2 tests in 2020, n (%)		
0	609,591 (80.9%)	99,863 (79.7%)
1	87,337 (11.6%)	14,115 (11.3%)
2	29,848 (4.0%)	4,908 (3.9%)
3	10,385 (1.4%)	1,871 (1.5%)
4-9	13,823 (1.8%)	3,649 (2.9%)
10+	2,167 (0.3%)	932 (0.7%)
Any other vaccine, n (%)†	495,996 (65.9%)	25,437 (20.3%)

† received at least one of the following vaccines since 2018: influenza, pneumococcal

polysaccharide vaccine 23, pneumococcal conjugated vaccine 13; * List of chronic diseases:

anemia, asthma, cancer, cardiac disease, stroke, dementia, diabetes, hypertension,

chronic liver disease, neuromuscular disease, renal disease, rheumatologic disease

mRNA vaccines	Unvaccinated
No. 753,151	No. 125,338

pulmonary disease, obesity, immunodeficiency, tuberculosis

273 Table 2: Distribution of 80 years and more cohort individuals by age group, sex, health region,
 274 municipality level European Deprivation index, number of chronic diseases*, number of SARS-
 275 CoV-2 tests performed in 2021, influenza or pneumococcal vaccine uptake in the last five years.

	mRNA	Unvaccinated
	No. 433,878	No. 26,942
Age (years), median (IQR)	84.0 (82.0 - 88.0)	86.0 (83.0 - 90.0)
Age group, (%)		
80-84	222,087 (51.2%)	10,342 (38.4%)
85-89	144,989 (33.4%)	9,197 (34.1%)
90-94	54,046 (12.5%)	5,301 (19.7%)
95+	12,756 (2.9%)	2,102 (7.8%)
Sex Male, n (%)	176,386 (40.7%)	9,628 (35.7%)
Region, n (%)		
Norte	159,051 (36.7%)	8,874 (32.9%)
Centro	91,672 (21.1%)	5,145 (19.1%)
Lisbon & Tagus Valley	141,890 (32.7%)	9,284 (34.5%)
Alentejo	24,013 (5.5%)	1,243 (4.6%)
Algarve	15,778 (3.6%)	1,594 (5.9%)
Missing	1,474 (0.3%)	802 (3.0%)
EDI Quintile, n (%)		
Q1 (least deprived)	75,836 (17.5%)	4,273 (15.9%)
Q2	67,922 (15.7%)	3,759 (14.0%)
Q3	65,827 (15.2%)	3,981 (14.8%)
Q4	120,327 (27.7%)	7,200 (26.7%)

	mRNA	Unvaccinated
	No. 433,878	No. 26,942
Q5 (most deprived)	102,492 (23.6%)	6,927 (25.7%)
Missing	1,474 (0.3%)	802 (3.0%)
Number of chronic diseases, n (%)		
0	45,350 (10.5%)	9,325 (34.6%)
1	84,118 (19.4%)	4,279 (15.9%)
2	112,888 (26.0%)	4,940 (18.3%)
3	96,043 (22.1%)	4,249 (15.8%)
4	56,889 (13.1%)	2,393 (8.9%)
5+	38,590 (8.9%)	1,756 (6.5%)
Number of SARS-CoV-2 tests in 2021, n (%)		
0	338,916 (78.1%)	17,503 (65.0%)
1	48,115 (11.1%)	3,665 (13.6%)
2	19,427 (4.5%)	1,976 (7.3%)
3	9,373 (2.2%)	1,135 (4.2%)
4-9	16,176 (3.7%)	2,355 (8.7%)
10+	1,871 (0.4%)	308 (1.1%)
Any other vaccine, n (%)†	418,873 (96.5%)	22,518 (83.6%)

† received at least one of the following vaccines since 2018: influenza, Pneumococcal polysaccharide vaccine 23, pneumococcal conjugated vaccine 13; * List of chronic diseases: anemia, asthma, cancer, cardiac disease, stroke, dementia, diabetes, hypertension, chronic liver disease, neuromuscular disease, renal disease, rheumatologic disease pulmonary disease, obesity, immunodeficiency, tuberculosis

277 Table 3: COVID-19 hospitalizations and COVID-19 related deaths, crude incidence rate (1000 person years),
 278 confounder-adjusted hazard ratios and vaccine effectiveness (%) by number of mRNA doses, for individuals
 279 aged 65-79 years old.

Vaccine Status	Person years	Nbr events	Rate per 1000 py	Rate ratio (95% CI)	Confounder-adjusted HR (95% CI)	Vaccine Effectiveness (95% CI)
COVID-19						
hospitalizations						
Unvaccinated	145,020	169	1.17	1	1	
Partial vaccination	59,064	15	0.25	0.21 (0.13 to 0.36)	0.22 (0.13 to 0.39)	78 (61 to 87)
Complete	133,715	11	0.08	0.07 (0.04 to 0.13)	0.06 (0.03 to 0.12)	94 (88 to 97)
vaccination						
Ratio HR complete vaccination versus partial					0.29 (0.13 to 0.66)	
COVID-19 related						
deaths						
Unvaccinated	145,057	90	0.62	1	1	
Partial vaccination	59,071	11	0.19	0.31 (0.16 to 0.37)	0.23 (0.12 to 0.44)	77 (56 to 88)
Complete	133,716	14	0.10	0.16 (0.09 to 0.28)	0.04 (0.02 to 0.08)	96 (92 to 98)
vaccination						
Ratio HR complete vaccination versus partial					0.19 (0.08 to 0.43)	

280 **COVID-19 hospitalization:** admission for at least 24h with COVID-19 as the primary diagnosis (ICD10 code U07.1); **COVID-19 related**
 281 **deaths:** All-cause death with positive RT-PCR test occurred within previous 30 days; **Partial vaccination:** 1 dose ≥ 14days or 2 dose
 282 <14 days; **Complete vaccination:** 2 dose ≥ 14days; **Rate:** per 1000 person years; **HR:** hazard ratio; **Confounder-adjusted HR:**
 283 confounder adjusted hazard ration obtained by time-dependent Cox regression with vaccine exposure as time dependent adjusted
 284 for age group, sex, health region, municipality level European Deprivation quintiles, number of chronic diseases, number of SARS-

285 CoV-2 tests performed in 2020, influenza or pneumococcal vaccine uptake in the last 3 years and time (7-day periods); **VE**: vaccine
 286 effectiveness $([1-HR]*100)$

287 Table 4 COVID-19 hospitalizations and COVID-19 related deaths, crude incidence rate (1000 person years),
 288 confounder-adjusted hazard ratios and vaccine effectiveness (%) by **number of mRNA doses and time in**
 289 **days since vaccine uptake, for individuals aged 80 years old or more.**

Vaccine Status	Person years	Nbr events	Rate per 1000 py	Rate ratio (95% CI)	Confounder-adjusted HR (95% CI)	Vaccine Effectiveness (95% CI)
COVID-19						
hospitalizations						
Unvaccinated	60,130	734	12.21	1	1	
Partial vaccination	32,766	39	1.19	0.10 (0.07 to 0.10)	0.45 (0.31 to 0.65)	55 (35 to 69)
Complete	129,047	43	0.33	0.03 (0.02 to 0.04)	0.18 (0.11 to 0.28)	82 (72 to 89)
vaccination						
Complete						
vaccination						
14 to 41 days	32,505	10	0.31	0.03 (0.01 to 0.05)	0.18 (0.09 to 0.36)	82 (64 to 91)
42 to 69 days	32,059	11	0.34	0.03 (0.02 to 0.05)	0.19 (0.09 to 0.39)	81 (61 to 91)
70 to 97 days	31,161	16	0.51	0.04 (0.03 to 0.07)	0.22 (0.12 to 0.43)	78 (57 to 88)
≥ 98 days	33,321	6	0.18	0.02 (0.01 to 0.03)	0.11 (0.04 to 0.29)	89 (71 to 96)
Ratio HR complete vaccination versus partial					0.41 (0.24 to 0.68)	
Ratio HR 2 doses ≥ 98 days versus 2 dose 14 to 41 days					0.62 (0.20 to 1.93)	
COVID-19 related						
deaths						
Unvaccinated	60,306	554	9.19	1	1	
Partial vaccination	32,791	34	1.04	0.11 (0.08 to 0.16)	0.44 (0.30 to 0.66)	56 (35 to 70)

Complete vaccination	129,057	91	0.71	0.08 (0.06 to 0.10)	0.19 (0.13 to 0.27)	81 (74 to 87)
Complete vaccination						
14 to 41 days	32,506	7	0.22	0.02 (0.01 to 0.05)	0.14 (0.07 to 0.32)	86 (68 to 93)
42 to 69 days	32,062	13	0.41	0.05 (0.03 to 0.08)	0.16 (0.09 to 0.30)	84 (70 to 91)
70 to 97 days	31,164	20	0.64	0.07 (0.05 to 0.11)	0.13 (0.08 to 0.23)	87 (77 to 92)
≥ 98 days	33,326	51	1.53	0.17 (0.13 to 0.22)	0.26 (0.17 to 0.40)	74 (60 to 83)
Ratio HR complete vaccination versus partial					0.42 (0.27 to 0.66)	
Ratio HR 2 doses ≥ 98 days versus 2 dose 14 to 41 days					1.80 (0.77 to 4.25)	
Ratio HR complete vaccination versus partial						

290 **COVID-19 hospitalization:** admission for at least 24h with COVID-19 as the primary diagnosis (ICD10 code U07.1); **COVID-19 related**
 291 **deaths:** All-cause death with positive RT-PCR test occurred within previous 30 days; **Partial vaccination:** 1 dose ≥ 14days or 2 dose
 292 <14 days; **Complete vaccination:** 2 dose ≥ 14days; **Rate:** per 1000 person years; **HR:** hazard ratio; **Adjusted HR:** confounder
 293 adjusted hazard ration obtained by time-dependent Cox regression with vaccine exposure as time dependent adjusted for age
 294 group, sex, health region, municipality level European Deprivation quintiles, number of chronic diseases, number of SARS-CoV-2
 295 tests performed in 2021, influenza or pneumococcal vaccine uptake in the last 3 years and time (7-day periods); **VE:** vaccine
 296 effectiveness $([1-HR]*100)$.